Skip to main content
. Author manuscript; available in PMC: 2014 Sep 1.
Published in final edited form as: J Thromb Haemost. 2013 Sep;11(9):1640–1646. doi: 10.1111/jth.12342

Figure 1. Effect of CYP2C19*2/CYP2C19*17 genotype combination on the formation of clopidogrel active metabolite level (A) and ADP-stimulated platelet aggregation (B) in members of the Pharmacogenomics of Anti-Platelet Intervention (PAPI) Study.

Figure 1

Vertical dashed lines are used to separate PAPI participants based on CYP2C19*2 genotype. * Due to linkage disequilibrium, there were no individuals with CYP2C19*2/CYP2C19*17 *1*2/*17*17, *2*2/*1*17, and *2*2/*17*17 genotype combinations.